Updates in the systemic treatment of hepatocellular carcinoma

Research output: Contribution to journalReview articlepeer-review


Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalEuropean Oncology and Haematology
Issue number2
StatePublished - 2018


  • Advanced disease
  • Cabozantinib
  • Hepatocellular carcinoma
  • Lenvatinib
  • Nivolumab
  • Ramucirumab
  • Regorafenib
  • Sorafenib

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Updates in the systemic treatment of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this